Poland· PL-100411289
Lenalidomide Accord
A lenalidomide product containing lenalidomidum, registered in Poland by Accord Healthcare S.L.U.. The same ATC class is registered in 16 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Lenalidomide is registered in 16 of 19 countries.
Countries holding a registration under ATC L04AX04 (lenalidomide), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 9 of them publish a price we can compare per daily dose
Lenalidomide · ATC L04AX04
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of lenalidomide costs, country by country.
Normalised to the WHO defined daily dose (10 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Lenalidomide · price per daily dose (10 mg)
USD · FX 28 Sept 2026
- CH Switzerland$47.45
The record
At a glance
URPL (Poland)- Active substance
- Lenalidomidum
- Manufacturer
- Accord Healthcare S.L.U.
- Country
- Poland (PL)
- ATC code
- L04AX04
- ATC class
- Lenalidomide
- Defined daily dose
- 10 mg, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05055565770856
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
397 interactions on record for lenalidomide.
Graded by severity as the source publishes them — 75 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Lenalidomide · interactions on record
397 records
- 75 severe
- 105 moderate
- 1 minor
- 216 info
Most severe, free to view
- ErythropoietinB03XA01severe
- Darbepoetin alfaB03XA02severe
- PeginesatideB03XA04severe
- C1-inhibitor, plasma derivedB06AC01severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c2034b14-fbe4-47b4-9f32-98f3ecb70117 GET /v1/drugs/c2034b14-fbe4-47b4-9f32-98f3ecb70117?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Kapsułki twarde",
"source": "urpl",
"strength": "5 mg",
"packaging": "Rpz ¦ EU/1/18/1316/003 ¦ 129784\n7 kaps.\n05055565770856 ¦ Rpz ¦ EU/1/18/1316/004 ¦ 129785\n21 kaps.",
"substance": "Lenalidomidum 5 mg",
"common_name": "Lenalidomidum",
"pl_product_id": "100411289",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about lenalidomide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.